Browsing Tag
Alexion Pharmaceuticals
14 posts
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the…
Alexion to acquire genetic medicine company LogicBio Therapeutics
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a…
AstraZeneca acquisition of Alexion comes under UK CMA’s scanner
The UK Competition and Markets Authority (CMA) has launched a phase 1 merger inquiry into $39 billion AstraZeneca’s…
AstraZeneca shareholders approve $39bn acquisition of Alexion
AstraZeneca has secured its shareholders’ approval for its previously announced $39 billion acquisition of US biopharma company Alexion…
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca…
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies…
Alexion Pharmaceuticals to acquire Portola Pharmaceuticals for $1.4bn
Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused…
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS…
Alexion Pharmaceuticals bags Ultomiris FDA approval for atypical HUS
Ultomiris FDA approval : Alexion Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for…
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for…